AR051950A1 - MULTI-PAD COMPRESSED WITH SEPARATING LAYERS - Google Patents

MULTI-PAD COMPRESSED WITH SEPARATING LAYERS

Info

Publication number
AR051950A1
AR051950A1 ARP050104673A AR051950A1 AR 051950 A1 AR051950 A1 AR 051950A1 AR P050104673 A ARP050104673 A AR P050104673A AR 051950 A1 AR051950 A1 AR 051950A1
Authority
AR
Argentina
Prior art keywords
drug
release
layer
tablet
containing layer
Prior art date
Application number
Other languages
Spanish (es)
Inventor
Claudio Gustavo Cerati
Juan A Vergez
Joaquina Faour
Silvia Krasuk
Original Assignee
Osmotica Pharmaceutical Argent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osmotica Pharmaceutical Argent filed Critical Osmotica Pharmaceutical Argent
Publication of AR051950A1 publication Critical patent/AR051950A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Un comprimido multicapa que provee multiples liberaciones de droga, donde la liberacion de droga de una capa que contiene droga no interfiere con la liberacion de droga de otra capa que contiene droga. El comprimido incluye al menos una capa de liberacion rápida y/o al menos una capa de liberacion extendida y una capa barrera inerte interpuesta de manera apilada, siendo el comprimido un comprimido de al menos tres capas en total. La droga en la capa de liberacion rápida puede ser la misma o diferente de la droga de la capa de liberacion extendida. La capa barrera inerte se adapta para desintegrarse, erosionarse, disolverse y/o de cualquier otra manera separarse completamente de cada capa que contiene droga dentro de pocos minutos después de la exposicion a un ambiente acuoso. La superficie de una capa que contiene droga queda expuesta después de la separacion de la capa barrera de manera que la liberacion de droga de la capa que contiene droga ocurre independientemente de la capa barrera y de cualquier otra capa que contiene droga presente. La capa de liberacion rápida se adapta para liberar su carga de droga dentro de menos de dos horas después del inicio de la liberacion, y la capa de liberacion extendida se adapta para liberar su carga de droga durante un período extendido de tiempo de unas pocas horas hasta aproximadamente 24 horas. La liberacion de droga de cada uno de las capas que contiene droga puede ser retrasada segun lo requiera el régimen terapéutico. Reivindicacion 83: El comprimido de cualquiera de las reivindicaciones 48 y 73, caracterizado porque la primera droga es ezetimibe y la segunda droga es seleccionada del grupo formado por lovastatín, simvastatina, pravastatín, fluvastatín, atorvastatín, mevastatín, rivastatín (cerivastatín), pitavastatín (nisvastatí, itavastatín), y rosuvastatín (visastatín).A multilayer tablet that provides multiple drug releases, where drug release from a drug-containing layer does not interfere with the drug release from another drug-containing layer. The tablet includes at least one rapid release layer and / or at least one extended release layer and an inert barrier layer interposed in a stacked manner, the tablet being a tablet of at least three layers in total. The drug in the rapid release layer may be the same or different from the drug in the extended release layer. The inert barrier layer is adapted to disintegrate, erode, dissolve and / or otherwise separate completely from each drug-containing layer within a few minutes after exposure to an aqueous environment. The surface of a drug-containing layer is exposed after separation of the barrier layer so that drug release from the drug-containing layer occurs independently of the barrier layer and any other drug-containing layer present. The rapid release layer is adapted to release its drug load within less than two hours after the onset of release, and the extended release layer is adapted to release its drug load for an extended period of time of a few hours. Up to about 24 hours. The drug release from each of the drug-containing layers can be delayed as required by the therapeutic regimen. Claim 83: The tablet of any of claims 48 and 73, characterized in that the first drug is ezetimibe and the second drug is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, mevastatin, rivastatin (cerivastatin), pitavastatin ( Nisvastatí, Itavastatin), and Rosuvastatin (Visastatin).

ARP050104673 2004-11-10 2005-11-08 MULTI-PAD COMPRESSED WITH SEPARATING LAYERS AR051950A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62666904P 2004-11-10 2004-11-10

Publications (1)

Publication Number Publication Date
AR051950A1 true AR051950A1 (en) 2007-02-21

Family

ID=36688111

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050104673 AR051950A1 (en) 2004-11-10 2005-11-08 MULTI-PAD COMPRESSED WITH SEPARATING LAYERS

Country Status (2)

Country Link
AR (1) AR051950A1 (en)
WO (1) WO2006089493A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
CN101801350A (en) 2007-08-13 2010-08-11 阿巴斯迪特宁医药有限公司 Abuse resistant drugs, using method and preparation method
ES2634421T3 (en) 2008-03-27 2017-09-27 Chase Pharmaceuticals Corporation Use and composition to treat dementia
EP2204170A1 (en) * 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising ezetimibe and simvastatin
IT1406328B1 (en) * 2010-12-23 2014-02-21 S I I T S R L Ora S I I T S R L Unipersonale DIVERSIFIED RELEASE MULTI-LAYER COMPRESS
WO2012118180A1 (en) 2011-03-03 2012-09-07 武田薬品工業株式会社 Laminated tablet and manufacturing method therefor
CN102764243B (en) * 2011-05-06 2014-10-29 上海医药工业研究院 Aspirin pulsed release pellets, its preparation and preparation method thereof
AU2013312749B2 (en) 2012-09-05 2018-01-18 Chase Pharmaceuticals Corporation Anticholinergic neuroprotective composition and methods
CA2907428A1 (en) 2013-03-15 2014-09-18 Inspirion Delivery Technologies, Llc Abuse deterrent compositions and methods of use
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
CN117858697A (en) * 2021-08-25 2024-04-09 曼肯制药有限公司 Pharmaceutical combination of PPAR agonist and sterol absorption inhibitor and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2100858B1 (en) * 1970-07-03 1975-06-06 Daiichi Seiyaku Co
US4503031A (en) * 1982-12-17 1985-03-05 Glassman Jacob A Super-fast-starting-sustained release tablet
DE4341442C2 (en) * 1993-12-04 1998-11-05 Lohmann Therapie Syst Lts Device for the controlled release of active substances and their use
DE19927688A1 (en) * 1999-06-17 2000-12-21 Gruenenthal Gmbh Multi-layered tablet containing tramadole and diclofenac, useful for treating pain, has separating layer between active ingredient layers
US7157100B2 (en) * 2002-06-04 2007-01-02 J.B. Chemicals & Pharmaceuticals Ltd. Pharmaceutical composition for controlled drug delivery system

Also Published As

Publication number Publication date
WO2006089493A1 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
AR051950A1 (en) MULTI-PAD COMPRESSED WITH SEPARATING LAYERS
Blagosklonny From rapalogs to anti-aging formula
ES2307463T1 (en) COMBINATION DOSAGE FORM CONTAINING A CHOLESTEROL REDUCING AGENT, A RENIN-ANGIOTENSIN INHIBITOR, AND AN ASPIRINE.
AR076835A1 (en) COMPOSITIONS OF ORAL DISINTEGRATION TABLETS THAT INCLUDE COMBINATIONS OF DRUGS IN ELEVATED AND REDUCED DOSE. METHOD.
Gillett Jr et al. Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity
Tiwari et al. Statins and myotoxicity: a therapeutic limitation
JP2005504064A5 (en)
WO2006084474A3 (en) A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor
ES2308040T3 (en) MULTI-PAD TABLE CONTAINING PARVASTATIN AND ASPIRINE AND PROCEDURE.
Girardi Can statins prevent pregnancy complications?
PE20000349A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF A STATIN AND ASPIRIN
PL1888427T3 (en) Child resistant package
RU2017106896A (en) ANTIMETANOGENIC COMPOSITIONS AND THEIR APPLICATION
AR058604A1 (en) MULTI-PAD COMPRESSED WITH TRIPLE RELEASE COMBINATION
AR052775A1 (en) BICAPA COMPRIMIDOS DE TELMISARTAN AND SIMVASTATINA
WO2008045170A3 (en) Statin and omega-3 fatty acids for reduction of apo-b levels
AR032739A1 (en) COMPOSITE LAMINATING AND PROCEDURE FOR ITS MANUFACTURE
CL2007003855A1 (en) COMPOSITION THAT INCLUDES A SUBSTRATE VEHICLE AND A DEPOSIT ON SUCH SUBSTRATE VEHICLE, WHERE SUCH DEPOSIT INCLUDES PARTICLES OF A PREGNAN DERIVATIVE COMPOUND; CAPSULE AND TABLET THAT UNDERSTAND IT; AND USE IN THE TREATMENT OF DISEASES T
AR071094A1 (en) CAPSULE FOR THE PREVENTION OF CARDIOVASCULAR DISEASES AND THEIR USE
ATE439832T1 (en) SOLID PHARMACEUTICAL DRUG FORMULATION CONTAINING DIACEREIN AND MELOXICAM
WO2009059717A3 (en) Pharmaceutical compositions containing statins and omega-3 fatty acids derivatives and their solid formulations for oral use
Marrs et al. Effects of lipid‐lowering therapy on reduction of cardiovascular events in patients with end‐stage renal disease requiring hemodialysis
AR055091A1 (en) COMPOSITIONS TO REDUCE THE INCIDENCE OF ARRITMIA INDUCED BY PHARMACOS
JP2008063322A5 (en)
CL2022000198A1 (en) Pharmaceutical composition comprising hmg-coa reductase inhibitors and fenofibrate

Legal Events

Date Code Title Description
FA Abandonment or withdrawal